

DAFTAR PUSTAKA

- Al Dweik, R., Stacey, D., Kohen, D. and Yaya, S., 2016. Factors affecting patient reporting of adverse drug reactions: a systematic review. *British Journal of Clinical Pharmacology*, 83(4), pp.875-883.
- Adisa, R. and Omitogun, T., 2019. Awareness, knowledge, attitude and practice of adverse drug reaction reporting among health workers and patients in selected primary healthcare centres in Ibadan, southwestern Nigeria. *Biomed Central Health Services Research*, 19(1).
- Almandil, N., 2016. Healthcare professionals' awareness and knowledge of adverse drug reactions and pharmacovigilance. *Saudi Medical Journal*, 37(12), pp.1359-1364.
- Anonim. 2012. Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury, *LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (Internet)*, Betesda. Diakses pada 27 Desember 2021 pukul 13.28 WIB
- Aronson, J., 2003. Joining the DoTS: new approach to classifying adverse drug reactions. *British Medical Journal*, 327(7425), pp.1222-1225.
- Bassi, P., Osakwe, A., Ogar, C., Elagbaje, C., Nwankwo, B., Balogun, S., Ntadom, G. and Isah, A., 2017. Impact of comorbidity on adverse reaction profile in a cohort of patients treated with Artemisinin combination therapies for uncomplicated malaria in Nigeria. *Pharmacology Research & Perspectives*, 5(2), p.e00302.
- BPOM RI., 2012. *Pedoman Monitoring Efek Samping Obat (MESO) Bagi Tenaga Kesehatan*. 1st ed. Jakarta: Direktorat Pengawasan Distribusi Produk Terapeutik dan Perbekalan Kesehatan Rumah Tangga Badan Pengawas Obat dan Makanan Republik Indonesia.
- BPOM RI., 2019. *Farmakovigilans (Keamanan Obat)*. Edisi 1. Jakarta: Direktorat Pengawasan Keamanan, Mutu, dan Ekspor Impor Obat, Narkotika, Psikotropika, Prekursor, dan Zat Adiktif Badan Pengawas Obat dan Makanan Republik Indonesia.
- BPOM RI., 2020. *Modul Pelatihan Untuk Tenaga Profesional Kesehatan*. Edisi 1. Jakarta: Direktorat Pengawasan Obat, Narkotika, Psikotropika, Prekursor, dan Zat Adiktif Badan Pengawas Obat dan Makanan Republik Indonesia.
- BPOM RI., 2021. *Buletin Berita MESO Volume 39*. Edisi 1. Jakarta: Pusat Farmakovigilans/MESO Nasional.
- BPOM RI., 2022a. *Modul Pelatihan Farmakovigilans Tingkat Dasar*. Edisi 1. Jakarta: Direktorat Pengawasan Obat, Narkotika, Psikotropika, Prekursor, dan Zat Adiktif Badan Pengawas Obat dan Makanan Republik Indonesia.

- BPOM RI., 2022b. *Modul Pelatihan Farmakovigilans Tingkat Lanjut*. Edisi 1. Jakarta: Direktorat Pengawasan Obat, Narkotika, Psikotropika, Prekursor, dan Zat Adiktif Badan Pengawas Obat dan Makanan Republik Indonesia.
- Chakraborty, B., 2015. Pharmacovigilance: A data mining approach to signal detection. *Indian Journal of Pharmacology*, 47(3), p.241.
- Cook, D., Lauzier, F., Rocha, M., Sayles, M. and Finfer, S., 2008. Serious adverse events in academic critical care research. *Canadian Medical Association Journal*, 178(9), pp.1181-1184.
- Davies, L., Spiers, G., Kingston, A., Todd, A., Adamson, J. and Hanratty, B., 2020. Adverse Outcomes of Polypharmacy in Older People: Systematic Review of Reviews. *Journal of the American Medical Directors Association*, 21(2), pp.181-187.
- Elkalmi, R., Hassali, M., Ibrahim, M., Widodo, R., Efan, Q. and Hadi, M., 2011. Pharmacy Students' Knowledge and Perceptions About Pharmacovigilance in Malaysian Public Universities. *American Journal of Pharmaceutical Education*, 75(5), p.96.
- Endang, R., Shilvi, A., Endah Purnamasari, R., Setiawaty, R. and Indarwanti, W., 2019. *Farmakovigilans : Panduan Deteksi dan Pelaporan Efek Samping Obat Untuk Tenaga Kesehatan*. Edisi 1. Jakarta: Badan Pengawas Obat dan Makanan Republik Indonesia.
- EMA, 2021., Medication Error. *European Medicines Agency : Science Medicines Health*. Diakses 28 Desember 2022
- Golder, S., Loke, Y., Wright, K. and Norman, G., 2016. Reporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic Review. *PLOS Medicine*, 13(9), p.e1002127.
- Guthrie, B., Makubate, B., Hernandez-Santiago, V. and Dreischulte, T., 2015. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. *BioMed Central Medicine*, 13(1).
- Hanlon, P., Corcoran, N., Rughani, G., Shah, A., Mair, F., Guthrie, B., Renton, J. and McAllister, D., 2021. Observed and expected serious adverse event rates in randomised clinical trials for hypertension: an observational study comparing trials that do and do not focus on older people. *The Lancet Healthy Longevity*, 2(7), pp.e398-e406.
- Härmark, L. and van Grootheest, A., 2008. Pharmacovigilance: methods, recent developments and future perspectives. *European Journal of Clinical Pharmacology*, 64(8), pp.743-752.
- Hazell, L. and Shakir, S., 2006. Under-Reporting of Adverse Drug Reactions. *Drug Safety*, 29(5), pp.385-396.

- Herdeiro, M. T., Polónia, J., Gestal-Otero, J. J., & Figueiras, A. 2008. Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. *Drug safety*, 31(4), 335–344. <https://doi.org/10.2165/00002018-200831040-00007>
- Inácio, P., Cavaco, A. and Airaksinen, M., 2016. The value of patient reporting to the pharmacovigilance system: a systematic review. *British Journal of Clinical Pharmacology*, 83(2), pp.227-246.
- Johansson, M. L., Hägg, S., & Wallerstedt, S. M. (2011). Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study. *BMC clinical pharmacology*, 11, 14. <https://doi.org/10.1186/1472-6904-11-14>
- Johnell, K. and Klarin, I., 2007. The Relationship between Number of Drugs and Potential Drug-Drug Interactions in the Elderly. *Drug Safety*, 30(10), pp.911-918.
- Khalil, H., Leversha, A., & Khalil, V. (2011). Drug allergy documentation--time for a change?. *International journal of clinical pharmacy*, 33(4), 610–613.
- Lavan, A. and Gallagher, P., 2015. Predicting risk of adverse drug reactions in older adults. *Therapeutic Advances in Drug Safety*, 7(1), pp.11-22.
- Li, R., Curtain, C., Bereznicki, L., & Zaidi, S. T. R. (2018). Community pharmacists' knowledge and perspectives of reporting adverse drug reactions in Australia: a cross-sectional survey. *International journal of clinical pharmacy*, 40(4), 878–889
- Lopez-Gonzalez, E., Herdeiro, M. T., Piñeiro-Lamas, M., Figueiras, A., & GREPHEPI group., 2015. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. *Drug safety*, 38(2), 189–196. <https://doi.org/10.1007/s40264-014-0256-6>
- Masnoon, N., Shakib, S., Kalisch-Ellett, L. and Caughey, G., 2017. What is polypharmacy? A systematic review of definitions. *BioMed Central Geriatrics*, 17(1).
- Murali, M., Suppes, S., Feldman, K. and Goldman, J., 2021. Utilization of the Naranjo scale to evaluate adverse drug reactions at a free-standing children's hospital. *PLOS ONE*, 16(1), p.e0245368.
- Nadew, S., Beyene, K. and Beza, S., 2020. Adverse drug reaction reporting practice and associated factors among medical doctors in government hospitals in Addis Ababa, Ethiopia. *PLOS ONE*, 15(1), p.e0227712.
- National Cancer Institute (NCI), 2017. Common Terminology Criteria for Adverse Events (CTCAE). 5th ed. *United States: U.S. Departement of Health and Human Services*.

- National Institute on Aging. 2022. *NIA Guidance on Clinical Trials*. [online].
<https://www.nia.nih.gov/research/grants-funding/nia-guidance-clinical-trials> Diakses 3 Februari 2022.
- Pal, S., Duncombe, C., Falzon, D. and Olsson, S., 2013. WHO Strategy for Collecting Safety Data in Public Health Programmes: Complementing Spontaneous Reporting Systems. *Drug Safety*, 36(2), pp.75-81.
- Pal, S., Olsson, S. and Brown, E., 2015. The Monitoring Medicines Project: A Multinational Pharmacovigilance and Public Health Project. *Drug Safety*, 38(4), pp.319-328.
- Qureshi, Z., Seoane-Vazquez, E., Rodriguez-Monguio, R., Svensson, K. and Szeinbach, S., 2011. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. *Pharmacoepidemiology and Drug Safety*, 20(7), pp.772-777.
- Radecka, A., Loughlin, L., Foy, M., de Ferraz Guimaraes, M., Sarinic, V., Di Giusti, M., Lesicar, M., Straus, S., Montero, D., Pallos, J., Ivanovic, J. and Raine, J., 2018. Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint Action. *Drug Safety*, 41(12), pp.1285-1302.
- Rusli, 2018. *Farmasi Klinik*. 1st ed. Jakarta: Kementerian Kesehatan Republik Indonesia.
- Saha, L., 2014. Role of Pharmacovigilance in Drug Development. *Enliven: Pharmacovigilance and Drug Safety*, 01(01).
- Sahu, R., Yadav, R., Prasad, P., Roy, A. and Chandrakar, S., 2014. Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance. *SpringerPlus*, 3(1).
- Salive, M., 2013. Multimorbidity in Older Adults. *Epidemiologic Reviews*, 35(1), pp.75-83.
- Schenker, Y., Park, S., Jeong, K., Pruskowski, J., Kavalieratos, D., Resick, J., Abernethy, A. and Kutner, J., 2019. Associations Between Polypharmacy, Symptom Burden, and Quality of Life in Patients with Advanced, Life-Limiting Illness. *Journal of General Internal Medicine*, 34(4), pp.559-566.
- Scurti, V., Romero, M. and Tognoni, G., 2011. A plea for a more epidemiological and patient-oriented pharmacovigilance. *European Journal of Clinical Pharmacology*, 68(1), pp.11-19.
- Sharif, M. J. H., Farrukh, M. J., Khan, F. U., Khan, Q., Ahmed, S. S., Kousar, R., Ahmad, T., Abid, S. M. A., Ashfaq, M., & Khan, S. A. (2022). Exploring the factors and barriers of healthcare professionals in tertiary care hospitals toward pharmacovigilance: a multicenter study from Khyber Pakhtunkhwa, Pakistan. *Current medical research and opinion*, 38(4), 595–605.

- Sharma M, Gupta SK. Post Marketing Surveillance cit. Gupta, S., 2011. *Textbook of Pharmacovigilance*. New Delhi: Jaypee Brothers Medical Publishers.
- Shrestha, S., Sharma, S., Bhasima, R., Kunwor, P., Adhikari, B. and Sapkota, B., 2020. Impact of an educational intervention on pharmacovigilance knowledge and attitudes among health professionals in a Nepal cancer hospital. *BMC Medical Education*, 20(1).
- Sonawane, K., Cheng, N. and Hansen, R., 2018. Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database. *Journal of Managed Care & Specialty Pharmacy*, 24(7), pp.682-690.
- Suke, S., Kosta, P. and Negi, H., 2015. Role of Pharmacovigilance in India: An overview. *Online Journal of Public Health Informatics*, 7(2).
- Tangamornsuksan, W., Lohitnavy, M., 2018. Association between HLA-B*1301 and dapsone-induced cutaneous adverse drug reactions. *JAMA Dermatology* 154, 441.
- Utaminigrum, W., 2015. *Evaluasi Adverse Drug Reactions (ADRs) Penyakit Kanker Payudara Dengan Kemoterapi Berbasis Antrasiklin di RSUD Prof. Dr. Margono Soekardjo Purwokerto*. Pharmacy, 12(01).
- Valderas, J., Starfield, B., Sibbald, B., Salisbury, C. and Roland, M., 2009. Defining Comorbidity: Implications for Understanding Health and Health Services. *The Annals of Family Medicine*, 7(4), pp.357-363.
- Valinciute-Jankauskiene, A., & Kubiliene, L., 2021. Qualitative Study of Community Pharmacists' and General Practitioners' Views toward Pharmacovigilance in Lithuania. *Healthcare (Basel, Switzerland)*, 9(8), 1072.
- Varallo, F., Planeta, C. and Mastroianni, P., 2017. Effectiveness Of Pharmacovigilance: Multifaceted Educational Intervention Related To The Knowledge, Skills And Attitudes Of Multidisciplinary Hospital Staff. *Clinics*, 72(1), pp.51-57.
- Wang, L., Varghese, S., Bassir, F., Lo, Y.-C., Ortega, C.A., Shah, S., Blumenthal, K.G., Phillips, E.J., Zhou, L., 2022. Stevens-Johnson Syndrome and toxic epidermal necrolysis: A systematic review of pubmed/Medline case reports from 1980 to 2020. *Frontiers in Medicine* 9.
- WHO, 2002. *Safety of Medicines : A Guide to Detecting and Reporting Adverse Drug Reactions*. 1st ed. Geneva: World Health Organization.
- WHO, 2002. *The Importance of Pharmacovigilance*. 1st ed. Geneva: World Health Organization.
- WHO, 2006. *The Safety of Medicines In Public Health Programmes*. 1st ed. France: World Health Organization.

Wu, L., Ingle, T., Liu, Z., Zhao-Wong, A., Harris, S., Thakkar, S., Zhou, G., Yang, J., Xu, J., Mehta, D., Ge, W., Tong, W. and Fang, H., 2019. Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA. *BioMed Central Bioinformatics*, 20(S2).